HULL HANS (Chief Business Officer) sold 7.6% of their position (17.94K shares) of PLIANT THERAPEUTICS, INC. on the open market
Open‑market sale worth $323.0K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 7/19/2023ACC: 0001209191-23-042829
Officer· Chief Business Officer
Since Jun 2020
-17.94K
Net shares
Net seller
$323.0K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
17.94K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−17.94K
Price / share
$18.01
Trade value
$323.03K
% of position
7.6%
7/17/2023
237.12K→219.18K
Total
Net shares
−17.94K
Net value
-$323.03K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/17/2023 | S · Sale | −17.94K | $18.01 | $323.03K | 7.6% | 237.12K | 219.18K |
| Total | −17.94K | -$323.03K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)3
Common Stock
IndirectShares owned13.98K
Common Stock
IndirectShares owned3.82K
Common Stock
IndirectShares owned13.98K
Total
31.79K indirect31.79K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 13.98K | Indirect |
| Common Stock | 3.82K | Indirect |
| Common Stock | 13.98K | Indirect |
| Total | 31.79K | 31.79K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported